CoChat

Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway

Open access
Narasimhan, Sneha, Holtzman, David M., Apostolova, Liana G., Cruchaga, Carlos, Masters, Colin L., Hardy, John, Villemagne, Victor L., Bell, Joanne, Cho, Min, Hampel, Harald · 2024 · Nature Neuroscience
Cited by 66

The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is a complex, progressive primary neurodegenerative disease. Since pivotal genetic studies in 1993, the ε4 allele of the apolipoprotein E gene (APOE ε4) has remained the strongest single genome-wide associated risk variant in AD. Scientific advances in APOE biology, AD pathophysiology and ApoE-targeted therapies have brought APOE to the forefront of research, with potential translation into routine AD clinical care. This contemporary Review will merge APOE research with the emerging AD clinical care pathway and discuss APOE genetic risk as a conduit to genomic-based precision medicine in AD, including ApoE’s influence in the ATX(N) biomarker framework of AD. We summarize the evidence for APOE as an important modifier of AD clinical–biological trajectories. We then illustrate the utility of APOE testing and the future of ApoE-targeted therapies in the next-generation AD clinical–diagnostic pathway. With the emergence of new AD therapies, understanding how APOE modulates AD pathophysiology will become critical for personalized AD patient care. This Review provides a framework for incorporating APOE into Alzheimer’s disease (AD) clinical care by bridging recent advances in APOE and AD research with emerging clinical applications for APOE testing and ApoE-targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41593-024-01669-5

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 92 references

Cited by

See all 66

Metadata

Authors
Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J., Cho, M., & Hampel, H.
Venue
Nature Neuroscience
Published
2024-06-19
Volume
27
Issue
7
Pages
1236-1252
ISSN
  • 1097-6256 (ISSN-L)
  • 1546-1726
OpenAlex
W4399810054
Cited by
66
References
92
FWCI
15.61
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway. https://app.cochat.ai/papers/10.1038/s41593-024-01669-5
The paper
Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J., Cho, M., & Hampel, H. (2024). Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway. Nature Neuroscience. https://doi.org/10.1038/s41593-024-01669-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.